Report of Foreign Issuer (6-k)
May 22 2018 - 9:30AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
6-K
REPORT OF
FOREIGN PRIVATE ISSUER
PURSUANT TO RULE
13a-16
OR
15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of May 2018
Commission File Number:
001-31368
SANOFI
(Translation of
registrant’s name into English)
54, rue La
Boétie, 75008 Paris, FRANCE
(Address of principal executive offices)
Indicate by check mark whether the registrant files or will file annual reports under cover Form
20-F
or Form
40-F.
Form
20-F ☒
Form
40-F ☐
Indicate by check mark if the registrant is submitting the Form
6-K
in paper as permitted by
Regulation
S-T
Rule 101(b)(1): ☐
Indicate by check mark if the registrant is
submitting the Form
6-K
in paper as permitted by Regulation
S-T
Rule 101(b)(7): ☐
Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information
to the Commission pursuant to Rule
12g3-2(b)
under the Securities Exchange Act of 1934.
Yes ☐ No ☒
If “Yes” marked, indicate below the file number assigned to the registrant in connection with Rule
12g3-2(b):
82-
In May 2018, Sanofi issued the press releases attached hereto as Exhibit 99.1 and 99.2 which are incorporated
herein by reference.
Exhibit List
|
|
|
|
|
Exhibit No.
|
|
Description
|
|
|
|
|
Exhibit 99.1
|
|
Press release dated May 21, 2018: New England Journal of Medicine publishes two positive Phase 3 trials showing Dupixent
®
(dupilumab) improved
moderate-to-severe
asthma
|
|
|
|
|
Exhibit 99.2
|
|
Press release dated May 16, 2018: Dupixent
®
(dupilumab) showed positive Phase 3 results in adolescents with inadequately controlled
moderate-to-severe
atopic dermatitis
|
2
Exhibit Index
|
|
|
|
|
Exhibit No.
|
|
Description
|
|
|
|
|
Exhibit 99.1
|
|
Press release dated May 21, 2018: New England Journal of Medicine publishes two positive Phase 3 trials showing Dupixent
®
(dupilumab) improved
moderate-to-severe
asthma
|
|
|
|
|
Exhibit 99.2
|
|
Press release dated May 16, 2018: Dupixent
®
(dupilumab) showed positive Phase 3 results in adolescents with inadequately controlled
moderate-to-severe
atopic dermatitis
|
3
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned, thereunto duly authorized.
|
|
|
|
|
|
|
|
|
Dated: May 22, 2018
|
|
|
|
SANOFI
|
|
|
|
|
|
|
|
By
|
|
/s/ Alexandra Roger
|
|
|
|
|
|
Name:
|
|
Alexandra Roger
|
|
|
|
|
|
Title:
|
|
Head of Securities Law and Capital Markets
|
4
Sanofi (PK) (USOTC:SNYNF)
Historical Stock Chart
From Mar 2024 to Apr 2024
Sanofi (PK) (USOTC:SNYNF)
Historical Stock Chart
From Apr 2023 to Apr 2024
